Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 9/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 7/20 | 0.34 |
| ▸ | GAK | O14976 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616809 | 1.00 | RIPK2 (0.37) | RIPK2PDE4DPIK3CAMTORATR | |
| SCHEMBL14616816 | 0.92 | RIPK2 (0.36) | RIPK2PIK3CAMTORATR | |
| SCHEMBL14616807 | 0.90 | RIPK2 (0.40) | RIPK2GAK | |
| SCHEMBL14616810 | 0.88 | RIPK2 (0.37) | RIPK2 | |
| SCHEMBL2551527 | 0.88 | MTOR (0.35) | PDE4DPIK3CAMTORATR | |
| SCHEMBL2553463 | 0.88 | MTOR (0.35) | PDE4DPIK3CAMTORATR | |
| SCHEMBL14616811 | 0.86 | TTK (0.38) | RIPK2ATRGAK | |
| SCHEMBL14616826 | 0.86 | RIPK2 (0.38) | RIPK2 | |
| SCHEMBL14616812 | 0.86 | RIPK2 (0.41) | RIPK2 | |
| SCHEMBL14616813 | 0.86 | RIPK2 (0.41) | RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885PDE4D 1258/4885PIK3CA 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.